ホーム » 研究業績/Publication » International Conference 2013

International Conference 2013

  • Alam M, Kuwata T, Ramirez K, Enomoto I, Maruta Y, Tanaka K, Rahman K, Egami Y, Kawanami Y, Murayama H, Shimura K, Matsuoka M, Matsushita S. Effects of Enfuvirtide resistant mutations on the sensitivity to neutralizing antibodies. 14th Kumamoto AIDS Seminar. 29-31 October 2013, Kumamoto.

  • Maruta Y, Kuwata T, Tanaka K, Nakahara Y, Ramirez K, Alam M, Egami Y, Suwa Y, Morioka H, Matsushita S. Post-attachment neutralization as a mechanism of efficient activities of scFv from anti-V3 monoclonal antibody. 14th Kumamoto AIDS Seminar. 29-31 October 2013, Kumamoto.

  • Tanaka K, Kuwata T, Maruta Y, Ramirez K, Kawanami Y, Enomoto I, Matsushita S. Miniaturization of antibodies against CD4-induced epitope on gp120. 14th Kumamoto AIDS Seminar. 29-31 October 2013, Kumamoto.

  • Ramirez K, Kuwata T, Maruta Y, Tanaka K, Alam M, Rahman K, Egami Y, Kawanami Y, Enomoto I, Tamamura H, Yoshimura K, Matsushita S. Can antibodies contribute to controlling infection with transmitted/founder virus? 14th Kumamoto AIDS Seminar.  29-31 October 2013, Kumamoto.

  • Kuwata T, Takaki K, Yoshimura K, Enomoto I, Wu F, Ourmanov I, Hirsch VM, Yokoyama M, Sato H, Matsushita S. Identification of the Env region responsible for the resistance to B404, a potent neutralizing antibody against SIV. 14th Kumamoto AIDS Seminar. 29-31 October 2013, Kumamoto.

  • Ramirez K, Kuwata T, Maruta Y, Tanaka K, Alam M, Rahman K, Kawanami Y, Enomoto I, Tamamura H, Yoshimura K, Matsushita S. Improving the brodality and potency of neutralizing anti-HIV-1 antibodies with a CD4 mimetic compound. AIDS Vaccine 2013. 7-10 October 2013. Barcelona, Spain.

  • Kuwata T, Takaki K, Yoshimura K, Enomoto I, Wu F, Ourmanov I, Hirsch VM, Yokoyama M, Sato H, Matsushita S. Analysis of Env regions important for binding and resistance to B404, a potent neutralizing antibody against SIV. AIDS Vaccine 2013. 7-10 October 2013. Barcelona, Spain.

  • Matsushita S., Yoshimura K., Maeda T., Murakami T., KD-1002 Principal Investigators and The Protocol Team of Quintiles.  Passive transfer of neutralizing monoclonal antibody KD-247 reduces plasma viral load in patientschronically infected with HIV-1: a phase-1b clinical study of a humanized monoclonal antibody KD-247 (KD-1002). 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) , 30 June –3 July 2013 , Kuala Lumpur.

     

  • Matsushita S., Yoshimura K., Maeda T., Murakami T., KD-1002 Principal Investigators and The Protocol Team of Quintiles. Passive transfer of neutralizing monoclonal antibody KD-247 reduces plasma viral load in patientschronically infected with HIV-1: a phase-1b clinical study of a humanized monoclonal antibody KD-247 (KD-1002).

  • Matsushita S.  Passive transfer of neutralizing monoclonal antibody KD-247 reduces plasma viral load in patients chronically infected with HIV-1:A Phase-1b clinical study of a humanized monoclonal antibody KD-247 (KD-1002).  IAS Towards an HIV Cure Symposium. 29-30 June 2013 , Kuala Lumpur.